TOP STORIES

• REGULATORY Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
  June 16, 2022

• REGULATORY Japan to Create Expert Panel to Ponder Drug Distribution and Pricing: Kanmin Taiwa
  June 15, 2022

• REGULATORY Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
  June 15, 2022

• BUSINESS Authorized Generics Gain Ground amid Quality Woes, Candesartan AG Share Up 10 Points
  June 14, 2022

• REGULATORY MSD’s Two-Time PMP Appeals for Lyfnua Rejected: DPO Minutes
  June 14, 2022

• ORGANIZATION FPMAJ Pushes Minimal Product Scope for Off-Year Re-Pricing, No Cut in 2% Buffer Zone: Annual Report
  June 13, 2022

• REGULATORY “Re-Do” Pricing Based on New Assumption Rather than Simple Cuts, DPP Lawmaker Says on Re-Pricing Rules
  June 10, 2022

• BUSINESS Idorsia Japan Set to File Its 2nd and 3rd Drugs Early Next Year, Eyes 80 Billion Yen Sales in 5 Years
  June 9, 2022

• BUSINESS Novartis Sees CML Med Scemblix as Growth Driver over Next Decade, 1st Line Use Holds Key
  June 8, 2022

• REGULATORY Japan OKs Honebuto Paper with No Mention of Drug Pricing; Stable Supply, Innovation, Biosimilar Promotion Spelled Out
  June 8, 2022

• REGULATORY Pharmacist LDP Candidate Eager for National Debate on Drug Pricing
  June 7, 2022

• REGULATORY Public-Private Confab Set for June 14, Talks on Data Utilization Expected
  June 7, 2022

• REGULATORY Scrap All Barriers, Annual Drug Re-Pricing to Boost International Competitiveness of Japan Pharma: LDP’s Jimi
  June 6, 2022

• BUSINESS Gilead Japan Eyes High-Single-Digit Annual Growth with Oncology as Third Biz Pillar
  June 3, 2022

• COMMENTARY New Zero Premium Rule Applied to 6 Drugs Since April Rollout, Is It Incentivizing Cost Disclosure?
  June 2, 2022

• BUSINESS Shashank Deshpande to Take Reins at Nippon Boehringer Ingelheim
  June 2, 2022

• REGULATORY Honebuto Draft Makes No Mention of Off-Year Re-Pricing or Buffer Zone, Calls for Stronger Drug Discovery Capabilities
  June 1, 2022

• BUSINESS Takeda to Transfer Spikevax Authorization to Moderna in Japan, 3-Way Purchase Deal to End
  June 1, 2022

• ACADEMIA NCGM, IQVIA Pair Up to Unravel “Long COVID” by Building Large-Scale Registry
  May 31, 2022

• REGULATORY Janssen’s COVID-19 Vaccine in Line for Japan Approval, No Supply Deal Signed
  May 31, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 66
• 67
• 68
• 69
• 70
• 71
• 72
• 73
• 74
• …
• Next ›
• 最終 »